Advanced Search

 

Study ID Status Title Patient Level Data
111772 Completed A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy
111773 Completed A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alemtuzumab
111774 Completed An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previously untreated B-cell CLL
111776 Completed An open-label, single-arm. multi-center phase 2 trial with ofatumumab in patients with relapsed/progressive Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapse/progression after autologous transplant
111789 Completed An open-label, non-randomized, pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment Study Listed on ClinicalStudyDataRequest.com
111809 Completed A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients with Gastroparesis Study Listed on ClinicalStudyDataRequest.com
111810 Completed A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without ST-segment elevation Study Listed on ClinicalStudyDataRequest.com
111815 Completed Immunogenicity and safety of GSK Biologicals’ dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 5 to 6-year-old children. Study Listed on ClinicalStudyDataRequest.com
111818 Completed An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects Study Listed on ClinicalStudyDataRequest.com
111821 Completed A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (formerly known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated with Antara™
111823 Completed A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
111827 Completed A single-arm, international, multi-center trial investigating the efficacy and safety of ofatumumab retreatment and maintenance in CLL patients who progressed following response or stable disease after ofatumumab treatment in Hx-CD20-406
111829 Completed A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral SB756050 administered for 6 days to Subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
111834 Completed A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma Study Listed on ClinicalStudyDataRequest.com
111848 Completed An open-label, non-randomized [11C]carfentanil PET study in healthy male subjects to investigate brain mu-opioid receptor occupancy, pharmacokinetics, and pharmacodynamics of single oral doses of GSK1521498 and naltrexone. Study Listed on ClinicalStudyDataRequest.com
111849 Completed A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of 10 days of repeat dosing of GSK1521498 in overweight or obese but otherwise healthy subjects. Study Listed on ClinicalStudyDataRequest.com
111850 Completed A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects with Over-Eating Behaviours. Study Listed on ClinicalStudyDataRequest.com
111852 Completed Immunogenicity and safety study of Kinrix® co-administered with Varivax® Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.